Pfizer cans twice-daily oral obesity program after half of patients leave trial while once...

[cafead]

via Pfizer is continuing to pinball between oral obesity assets. Months after making twice-daily danuglipron its top prospect, the Big Pharma has dropped the program after more than half of people taking the drug candidate dropped out of a midphase clinical trial.

article source